Intercontinental Exchange: Q2 Earnings Insights

  Intercontinental Exchange (NYSE:ICE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

 

Intercontinental Exchange (NYSE:ICE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Intercontinental Exchange beat estimated earnings by 3.94%, reporting an EPS of $1.32 versus an estimate of $1.27.

Revenue was up $107.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.01 which was followed by a 1.79% drop in the share price the next day.

Here’s a look at Intercontinental Exchange’s past performance:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 1.42 1.32 1.22 1.17
EPS Actual 1.43 1.34 1.30 1.16
Revenue Estimate 1.89B 1.83B 1.75B 1.72B
Revenue Actual 1.90B 1.84B 1.80B 1.71B

To track all earnings releases for Intercontinental Exchange visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

AbbVie Announced FDA Approved the Use of Imbruvica for the Treatment of Pediatric Patients One Year and Older With cGVHD After Failure of One or More Lines of Systemic Therapy

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

ABBV